Atlas Trials

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

Clinical trial NCT05972993 · COMPLETED

Trial details

NCT number
NCT05972993
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19
Start date
2023-08-07
Primary completion
2024-05-09
Enrollment
114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.